DOCSLIB.ORG

Androgen Receptor and Foxa1 Interaction Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Androgen Receptor and Foxa1 Interaction Study Androgen Receptor and FoxA1 Interaction Study Marko Laakso Biswajyoti Sahu Kristian Ovaska Olli A. J¨anne Sampsa Hautaniemi July 10, 2011 Abstract This Anduril analysis compares androgen receptor (AR) and FoxA1 binding sites in LNCaP-1F5 prostate cancer cells. Binding site data have been integrated with expression profiles obtained for the DHT stimulus. This document is generated automatically by Anduril (Engine 1.2.2). Contents 1 Expression analysis for AR 5 2 Summary of DEGs in AR 6 3 List of differentially expressed genes 6 3.1 Gene set: fcC fcOver..................................................6 3.2 Gene set: fcC fcUnder.................................................6 3.3 Gene set: fcA1 fcOver.................................................6 3.4 Gene set: fcA1 fcUnder................................................7 3.5 Gene set: fcE fcOver..................................................7 3.6 Gene set: fcE fcUnder.................................................8 4 Expression analysis for GR 9 5 Summary of DEGs in GR 9 6 List of differentially expressed genes 9 6.1 Gene set: fcsiCx fcOver................................................9 6.2 Gene set: fcsiCx fcUnder............................................... 10 6.3 Gene set: fcsiFx fcOver................................................ 10 6.4 Gene set: fcsiFx fcUnder................................................ 11 7 Gene set overlaps 14 8 Gene set comparison 17 9 Candidate report for Unique DEGs for AR 19 9.1 Moksiskaan candidate pathway............................................ 19 9.1.1 GO enrichment of the candidate pathway.................................. 22 9.2 Candidate genes.................................................... 27 9.2.1 GO enrichment of all candidates....................................... 35 10 Candidate report for Unique DEGs for AR with siFOXA1 36 10.1 Moksiskaan candidate pathway............................................ 36 10.1.1 GO enrichment of the candidate pathway.................................. 38 10.2 Candidate genes.................................................... 41 10.2.1 GO enrichment of all candidates....................................... 53 11 Candidate report for Common DEGs for AR and siFOXA1 56 11.1 Moksiskaan candidate pathway............................................ 56 11.1.1 GO enrichment of the candidate pathway.................................. 61 11.2 Candidate genes.................................................... 66 11.2.1 GO enrichment of all candidates....................................... 71 2 12 ChIP-seq peaks 73 12.1 AR DHT binding sites................................................. 74 12.2 FoxA1 binding sites.................................................. 76 12.3 AR binding sites (siFOXA1).............................................. 78 12.4 FoxA1 binding sites (siFOXA1)............................................ 81 12.5 AR and FoxA1 binding site overlaps......................................... 83 12.6 AR and FoxA1 binding site overlaps (up)...................................... 85 12.7 AR and FoxA1 binding site overlaps (down)..................................... 87 12.8 AR without FoxA1 binding site overlaps....................................... 89 12.9 AR without FoxA1 binding site overlaps (up).................................... 91 12.10AR without FoxA1 binding site overlaps (down).................................. 93 12.11FoxA1 without AR binding site overlaps....................................... 95 12.12FoxA1 without AR binding site overlaps (up).................................... 97 12.13FoxA1 without AR binding site overlaps (down).................................. 99 12.14AR and FoxA1 siFOXA1 binding site overlaps.................................... 101 12.15AR and FoxA1 siFOXA1 binding site overlaps (up)................................. 103 12.16AR and FoxA1 siFOXA1 binding site overlaps (down)............................... 105 12.17AR without FoxA1 siFOXA1 binding site overlaps................................. 107 12.18AR without FoxA1 siFOXA1 binding site overlaps (up).............................. 110 12.19AR without FoxA1 siFOXA1 binding site overlaps (down)............................. 112 12.20FoxA1 without AR siFOXA1 binding site overlaps................................. 114 12.21FoxA1 without AR siFOXA1 binding site overlaps (up).............................. 116 12.22FoxA1 without AR siFOXA1 binding site overlaps (down)............................. 118 12.23AR and AR siFOXA1 binding site overlaps..................................... 120 12.24AR and AR siFOXA1 binding site overlaps (up).................................. 122 12.25AR and AR siFOXA1 binding site overlaps (down)................................. 124 12.26AR without AR siFOXA1 binding site overlaps................................... 126 12.27AR without AR siFOXA1 binding site overlaps (up)................................ 128 12.28AR without AR siFOXA1 binding site overlaps (down)............................... 130 12.29AR siFOXA1 without AR binding site overlaps................................... 132 12.30AR siFOXA1 without AR binding site overlaps (up)................................ 135 12.31AR siFOXA1 without AR binding site overlaps (down)............................... 137 12.32FoxA1 and FoxA1 siFOXA1 binding site overlaps.................................. 139 12.33FoxA1 and FoxA1 siFOXA1 binding site overlaps (up)............................... 141 12.34FoxA1 and FoxA1 siFOXA1 binding site overlaps (down)............................. 143 12.35FoxA1 without FoxA1 siFOXA1 binding site overlaps................................ 145 12.36FoxA1 without FoxA1 siFOXA1 binding site overlaps (up)............................. 147 12.37FoxA1 without FoxA1 siFOXA1 binding site overlaps (down)........................... 149 12.38FoxA1 siFOXA1 without FoxA1 binding site overlaps................................ 151 12.39FoxA1 siFOXA1 without FoxA1 binding site overlaps (up)............................. 153 12.40FoxA1 siFOXA1 without FoxA1 binding site overlaps (down)........................... 155 3 12.41AR and FoxA1 binding site overlaps (stable).................................... 157 12.42AR without FoxA1 binding site overlaps (stable).................................. 159 12.43FoxA1 without AR binding site overlaps (stable).................................. 161 12.44AR and AR siFOXA1 binding site overlaps (stable)................................. 163 12.45AR without AR siFOXA1 binding site overlaps (stable).............................. 165 12.46AR siFOXA1 without AR binding site overlaps (stable).............................. 167 12.47FoxA1 and FoxA1 siFOXA1 binding site overlaps (stable)............................. 170 12.48FoxA1 without FoxA1 siFOXA1 binding site overlaps (stable)........................... 172 12.49FoxA1 siFOXA1 without FoxA1 binding site overlaps (stable)........................... 174 12.50AR and FoxA1 siFOXA1 binding site overlaps (stable)............................... 176 12.51AR without FoxA1 siFOXA1 binding site overlaps (stable)............................. 178 12.52FoxA1 without AR siFOXA1 binding site overlaps (stable)............................. 181 12.53GR DEX binding sites................................................. 183 12.54GR DEX binding sites (siFOXA1).......................................... 185 12.55GR and GR siFOXA1 binding site overlaps..................................... 188 12.56GR without GR siFOXA1 binding site overlaps................................... 190 12.57GR siFOXA1 without GR binding site overlaps................................... 192 12.58AR and FOXA1 overlaps unique for AR parental.................................. 195 13 AR versus AR siFOXA1 197 14 Expression comparision 199 14.1 Box plots........................................................ 200 15 System configuration 213 4 1 Expression analysis for AR Group Definition Description ce median(ce1, ce2) AR controls for FoxA1 study cd median(cd1, cd2) AR cases (DHT) for FoxA1 study a1e median(a1e1, a1e2) siFOXA1 controls a1d median(a1d1, a1d2) siFOXA1 cases fcC ratio(cd/ce) AR DHT samples divided by their controls fcA1 ratio(a1d/a1e) siFOXA1 DHT samples divided by their controls fcE ratio(ce/a1e) siFOXA1 samples divided by the parental cells Table 1: Sample groups a1d1 a1d2 a1d (median) a1e2 fcA1 (ratio) a1e1 a1e (median) fcE (ratio) ce (median) ce1 fcC (ratio) ce2 cd1 cd (median) cd2 5 2 Summary of DEGs in AR Gene set Size fcC fcOver 195 fcC fcUnder 106 fcA1 fcOver 242 fcA1 fcUnder 175 fcE fcOver 188 fcE fcUnder 199 3 List of differentially expressed genes Overexpressed genes are sorted with the most overexpressed first and underexpressed genes with the most underexpressed first. Genes go by the column first and then by row. 3.1 Gene set: fcC fcOver Number of genes: 195 PHGR1 C1orf116 LPAR3 ATAD2 PYGB HSD17B11 RP11-546D6.2 SMPD2 FKBP5 SPDEF HES1 PPFIBP2 PAQR4 AC068353.1 CAMKK2 PTGER4 PGC DBI KLK3 JAG1 ACAD8 AL121833.1 MKLN1 MRPS18A SLC45A3 MBOAT2 NBL1 ELOVL2 HIVEP1 GDF15 VWF HMG20B S100P STK39 CEBPD BRP44 APP WDYHV1 CEBPG TNS3 NCAPD3 EXTL2 CNTNAP2 SLC2A12 SHROOM3 MTOR VIPR1 BMPR1B SAT1 PECI TMPRSS2 RP11-312J18.5 DHCR24 CTD-2048F20.1 CORO1B TACC2 MICAL1 TUBA3D TBC1D4 KLK2 HEBP2 ZBTB24 STRA13 TIPARP TSKU ZMIZ1 CTD-2653M23.1 DNAJB9 ABHD3 SGK1 CBLL1 MERTK PMEPA1 KRT8 MLPH PFKFB2 KIF22 TEX2 GLRX SETBP1 ST6GALNAC1 TRPM8 C9orf152 PRKCH MAPK6 REPS2 C15orf23 SEMA4A ALDH1A3 TM4SF1 ISG20 SMS CRIP2 AC020915.4 UGT2B28 SEPP1 CLDN8 RP11-529H2.2 HOMER2 CENPN HERC5 ATP1A1 RAB3IP UBE2G1 SORD NFKBIA FAM43A
Load more

Recommended publications
  • Stat4 Consensus and Mutant Oligonucleotides
    SANTA CRUZ BIOTECHNOLOGY, INC. Stat4 Consensus and Mutant Oligonucleotides BACKGROUND PRODUCT Electrophoretic mobility shift assays (EMSAs), also known as gel shift assays, Stat4 CONSENSUS OLIGONUCLEOTIDE: sc-2569 provide a relatively straightforward and sensitive method for studying bind- ■ binding site for Stat4 (3) ing interactions between transcription factors and consensus DNA binding elements. For such studies, DNA probes are provided as double-stranded 5’ — GAG CCT GA T TTC CCC GAA AT G ATG AGC TAG — 3’ oligonucleotides designed with 5' OH blunt ends to facilitate labeling to high 3’ — CTC GGA C T A AAG GGG CTT TA C TAC TCG ATC — 5’ specific activity with polynucleotide kinase. These are constructed both with Stat4 MUTANT OLIGONUCLEOTIDE: sc-2570 specific DNA binding consensus sequences for various transcription factors ■ identical to sc-2569 with the exception of a “CCC” “TTT” substitution in and as control or “mutant” probes in which one or more nucleotides mapping → the Stat4 binding motif (3) within the consensus binding site has been substituted. 5’ — GAG CCT GA T TTC TTT GAA AT G ATG AGC TAG — 3’ REFERENCES 3’ — CTC GGA C T A AAG AAA CTT TA C TAC TCG ATC — 5’ 1. Dignam, J.D., et al. 1983. Accurate transcription initiation by RNA poly- merase II in a soluble extract from isolated mammalian nuclei. Nucleic SELECT PRODUCT CITATIONS Acids Res. 11: 1475-1489. 1. Ahn, H.J., et al. 1998. Requirement for distinct Janus kinases and STAT 2. Murre, C., et al. 1991. B cell- and myocyte-specific E2-box-binding factors proteins in T cell proliferation versus IFN-g production following IL-12 contain E12/E47-like subunits.
    [Show full text]
  • Core Transcriptional Regulatory Circuitries in Cancer
    Oncogene (2020) 39:6633–6646 https://doi.org/10.1038/s41388-020-01459-w REVIEW ARTICLE Core transcriptional regulatory circuitries in cancer 1 1,2,3 1 2 1,4,5 Ye Chen ● Liang Xu ● Ruby Yu-Tong Lin ● Markus Müschen ● H. Phillip Koeffler Received: 14 June 2020 / Revised: 30 August 2020 / Accepted: 4 September 2020 / Published online: 17 September 2020 © The Author(s) 2020. This article is published with open access Abstract Transcription factors (TFs) coordinate the on-and-off states of gene expression typically in a combinatorial fashion. Studies from embryonic stem cells and other cell types have revealed that a clique of self-regulated core TFs control cell identity and cell state. These core TFs form interconnected feed-forward transcriptional loops to establish and reinforce the cell-type- specific gene-expression program; the ensemble of core TFs and their regulatory loops constitutes core transcriptional regulatory circuitry (CRC). Here, we summarize recent progress in computational reconstitution and biologic exploration of CRCs across various human malignancies, and consolidate the strategy and methodology for CRC discovery. We also discuss the genetic basis and therapeutic vulnerability of CRC, and highlight new frontiers and future efforts for the study of CRC in cancer. Knowledge of CRC in cancer is fundamental to understanding cancer-specific transcriptional addiction, and should provide important insight to both pathobiology and therapeutics. 1234567890();,: 1234567890();,: Introduction genes. Till now, one critical goal in biology remains to understand the composition and hierarchy of transcriptional Transcriptional regulation is one of the fundamental mole- regulatory network in each specified cell type/lineage.
    [Show full text]
  • Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug
    cancers Article Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia David G.J. Cucchi 1 , Costa Bachas 1 , Marry M. van den Heuvel-Eibrink 2,3, Susan T.C.J.M. Arentsen-Peters 3, Zinia J. Kwidama 1, Gerrit J. Schuurhuis 1, Yehuda G. Assaraf 4, Valérie de Haas 3 , Gertjan J.L. Kaspers 3,5 and Jacqueline Cloos 1,* 1 Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands; [email protected] (D.G.J.C.); [email protected] (C.B.); [email protected] (Z.J.K.); [email protected] (G.J.S.) 2 Department of Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital, 3015 CN Rotterdam, The Netherlands; [email protected] 3 Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands; [email protected] (S.T.C.J.M.A.-P.); [email protected] (V.d.H.); [email protected] (G.J.L.K.) 4 The Fred Wyszkowski Cancer Research, Laboratory, Department of Biology, Technion-Israel Institute of Technology, 3200003 Haifa, Israel; [email protected] 5 Emma’s Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, 1081 HV Amsterdam, The Netherlands * Correspondence: [email protected] Received: 21 April 2020; Accepted: 12 May 2020; Published: 15 May 2020 Abstract: Novel treatment strategies are of paramount importance to improve clinical outcomes in pediatric AML. Since chemotherapy is likely to remain the cornerstone of curative treatment of AML, insights in the molecular mechanisms that determine its cytotoxic effects could aid further treatment optimization.
    [Show full text]
  • A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2007-12-28 A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation Frederick Albert Schroeder University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Amino Acids, Peptides, and Proteins Commons, Cells Commons, Enzymes and Coenzymes Commons, Genetic Phenomena Commons, Mental Disorders Commons, Nervous System Commons, and the Therapeutics Commons Repository Citation Schroeder FA. (2007). A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/7bk0-a687. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/370 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. A Dissertation Presented by Frederick Albert Schroeder Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences Worcester, Massachusetts, USA in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY December 28, 2007 Program in Neuroscience A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs A Dissertation Presented By Frederick Albert Schroeder Approved as to style and content by: _____________________________________ Alonzo Ross, Ph.D., Chair of Committee _____________________________________ Pradeep Bhide, Ph.D., Member of Committee _____________________________________ Craig L.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Proteasome System of Protein Degradation and Processing
    ISSN 0006-2979, Biochemistry (Moscow), 2009, Vol. 74, No. 13, pp. 1411-1442. © Pleiades Publishing, Ltd., 2009. Original Russian Text © A. V. Sorokin, E. R. Kim, L. P. Ovchinnikov, 2009, published in Uspekhi Biologicheskoi Khimii, 2009, Vol. 49, pp. 3-76. REVIEW Proteasome System of Protein Degradation and Processing A. V. Sorokin*, E. R. Kim, and L. P. Ovchinnikov Institute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Moscow Region, Russia; E-mail: [email protected]; [email protected] Received February 5, 2009 Abstract—In eukaryotic cells, degradation of most intracellular proteins is realized by proteasomes. The substrates for pro- teolysis are selected by the fact that the gate to the proteolytic chamber of the proteasome is usually closed, and only pro- teins carrying a special “label” can get into it. A polyubiquitin chain plays the role of the “label”: degradation affects pro- teins conjugated with a ubiquitin (Ub) chain that consists at minimum of four molecules. Upon entering the proteasome channel, the polypeptide chain of the protein unfolds and stretches along it, being hydrolyzed to short peptides. Ubiquitin per se does not get into the proteasome, but, after destruction of the “labeled” molecule, it is released and labels another molecule. This process has been named “Ub-dependent protein degradation”. In this review we systematize current data on the Ub–proteasome system, describe in detail proteasome structure, the ubiquitination system, and the classical ATP/Ub- dependent mechanism of protein degradation, as well as try to focus readers’ attention on the existence of alternative mech- anisms of proteasomal degradation and processing of proteins.
    [Show full text]
  • UNIVERSITY of CALIFORNIA, IRVINE Combinatorial Regulation By
    UNIVERSITY OF CALIFORNIA, IRVINE Combinatorial regulation by maternal transcription factors during activation of the endoderm gene regulatory network DISSERTATION submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Biological Sciences by Kitt D. Paraiso Dissertation Committee: Professor Ken W.Y. Cho, Chair Associate Professor Olivier Cinquin Professor Thomas Schilling 2018 Chapter 4 © 2017 Elsevier Ltd. © 2018 Kitt D. Paraiso DEDICATION To the incredibly intelligent and talented people, who in one way or another, helped complete this thesis. ii TABLE OF CONTENTS Page LIST OF FIGURES vii LIST OF TABLES ix LIST OF ABBREVIATIONS X ACKNOWLEDGEMENTS xi CURRICULUM VITAE xii ABSTRACT OF THE DISSERTATION xiv CHAPTER 1: Maternal transcription factors during early endoderm formation in 1 Xenopus Transcription factors co-regulate in a cell type-specific manner 2 Otx1 is expressed in a variety of cell lineages 4 Maternal otx1 in the endodermal conteXt 5 Establishment of enhancers by maternal transcription factors 9 Uncovering the endodermal gene regulatory network 12 Zygotic genome activation and temporal control of gene eXpression 14 The role of maternal transcription factors in early development 18 References 19 CHAPTER 2: Assembly of maternal transcription factors initiates the emergence 26 of tissue-specific zygotic cis-regulatory regions Introduction 28 Identification of maternal vegetally-localized transcription factors 31 Vegt and OtX1 combinatorially regulate the endodermal 33 transcriptome iii
    [Show full text]
  • Role of Phytochemicals in Colon Cancer Prevention: a Nutrigenomics Approach
    Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Marjan J van Erk Promotor: Prof. Dr. P.J. van Bladeren Hoogleraar in de Toxicokinetiek en Biotransformatie Wageningen Universiteit Co-promotoren: Dr. Ir. J.M.M.J.G. Aarts Universitair Docent, Sectie Toxicologie Wageningen Universiteit Dr. Ir. B. van Ommen Senior Research Fellow Nutritional Systems Biology TNO Voeding, Zeist Promotiecommissie: Prof. Dr. P. Dolara University of Florence, Italy Prof. Dr. J.A.M. Leunissen Wageningen Universiteit Prof. Dr. J.C. Mathers University of Newcastle, United Kingdom Prof. Dr. M. Müller Wageningen Universiteit Dit onderzoek is uitgevoerd binnen de onderzoekschool VLAG Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Marjan Jolanda van Erk Proefschrift ter verkrijging van graad van doctor op gezag van de rector magnificus van Wageningen Universiteit, Prof.Dr.Ir. L. Speelman, in het openbaar te verdedigen op vrijdag 1 oktober 2004 des namiddags te vier uur in de Aula Title Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Author Marjan Jolanda van Erk Thesis Wageningen University, Wageningen, the Netherlands (2004) with abstract, with references, with summary in Dutch ISBN 90-8504-085-X ABSTRACT Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Specific food compounds, especially from fruits and vegetables, may protect against development of colon cancer. In this thesis effects and mechanisms of various phytochemicals in relation to colon cancer prevention were studied through application of large-scale gene expression profiling. Expression measurement of thousands of genes can yield a more complete and in-depth insight into the mode of action of the compounds.
    [Show full text]
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • Supplementary Table S1. Correlation Between the Mutant P53-Interacting Partners and PTTG3P, PTTG1 and PTTG2, Based on Data from Starbase V3.0 Database
    Supplementary Table S1. Correlation between the mutant p53-interacting partners and PTTG3P, PTTG1 and PTTG2, based on data from StarBase v3.0 database. PTTG3P PTTG1 PTTG2 Gene ID Coefficient-R p-value Coefficient-R p-value Coefficient-R p-value NF-YA ENSG00000001167 −0.077 8.59e-2 −0.210 2.09e-6 −0.122 6.23e-3 NF-YB ENSG00000120837 0.176 7.12e-5 0.227 2.82e-7 0.094 3.59e-2 NF-YC ENSG00000066136 0.124 5.45e-3 0.124 5.40e-3 0.051 2.51e-1 Sp1 ENSG00000185591 −0.014 7.50e-1 −0.201 5.82e-6 −0.072 1.07e-1 Ets-1 ENSG00000134954 −0.096 3.14e-2 −0.257 4.83e-9 0.034 4.46e-1 VDR ENSG00000111424 −0.091 4.10e-2 −0.216 1.03e-6 0.014 7.48e-1 SREBP-2 ENSG00000198911 −0.064 1.53e-1 −0.147 9.27e-4 −0.073 1.01e-1 TopBP1 ENSG00000163781 0.067 1.36e-1 0.051 2.57e-1 −0.020 6.57e-1 Pin1 ENSG00000127445 0.250 1.40e-8 0.571 9.56e-45 0.187 2.52e-5 MRE11 ENSG00000020922 0.063 1.56e-1 −0.007 8.81e-1 −0.024 5.93e-1 PML ENSG00000140464 0.072 1.05e-1 0.217 9.36e-7 0.166 1.85e-4 p63 ENSG00000073282 −0.120 7.04e-3 −0.283 1.08e-10 −0.198 7.71e-6 p73 ENSG00000078900 0.104 2.03e-2 0.258 4.67e-9 0.097 3.02e-2 Supplementary Table S2.
    [Show full text]